X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11030) 11030
Book Review (2421) 2421
Publication (898) 898
Newsletter (540) 540
Newspaper Article (491) 491
Book Chapter (126) 126
Book / eBook (76) 76
Trade Publication Article (44) 44
Conference Proceeding (28) 28
Magazine Article (26) 26
Dissertation (14) 14
Government Document (4) 4
Data Set (2) 2
Reference (2) 2
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8848) 8848
humans (8752) 8752
hematology (5158) 5158
oncology (4620) 4620
male (4047) 4047
female (3832) 3832
chronic myeloid leukemia (3797) 3797
leukemia (3670) 3670
chronic myelogenous leukemia (3660) 3660
adult (3534) 3534
middle aged (3441) 3441
chronic myeloid-leukemia (2797) 2797
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (2496) 2496
cancer (2331) 2331
imatinib mesylate (2300) 2300
aged (2170) 2170
leukemia, myelogenous, chronic, bcr-abl positive - genetics (1938) 1938
imatinib (1928) 1928
research (1798) 1798
care and treatment (1693) 1693
antineoplastic agents - therapeutic use (1650) 1650
adolescent (1574) 1574
benzamides (1564) 1564
leukemia, myelogenous, chronic, bcr-abl positive - pathology (1483) 1483
transplantation (1482) 1482
pyrimidines - therapeutic use (1463) 1463
treatment outcome (1456) 1456
hemic and lymphatic diseases (1378) 1378
bcr-abl (1343) 1343
animals (1260) 1260
stem cells (1246) 1246
fusion proteins, bcr-abl - genetics (1243) 1243
piperazines - therapeutic use (1241) 1241
cml (1170) 1170
genetic aspects (1086) 1086
protein kinase inhibitors - therapeutic use (1061) 1061
mutation (1056) 1056
prognosis (1022) 1022
therapy (1003) 1003
acute lymphoblastic-leukemia (952) 952
analysis (948) 948
immunology (948) 948
abridged index medicus (944) 944
health aspects (919) 919
dasatinib (908) 908
leukemia, myelogenous, chronic, bcr-abl positive - therapy (900) 900
bone marrow (893) 893
young adult (893) 893
medicine & public health (868) 868
transplantation, homologous (805) 805
child (799) 799
hematopoietic stem cells (777) 777
drug therapy (772) 772
hematology, oncology and palliative medicine (752) 752
tyrosine (745) 745
philadelphia chromosome (744) 744
bone-marrow-transplantation (743) 743
risk factors (743) 743
acute myeloid-leukemia (739) 739
mice (730) 730
aged, 80 and over (727) 727
chronic-phase (723) 723
antineoplastic agents (711) 711
kinases (705) 705
philadelphia-chromosome (703) 703
patients (686) 686
tyrosine kinase inhibitors (685) 685
chemotherapy (676) 676
antimitotic agents (661) 661
retrospective studies (657) 657
nilotinib (640) 640
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (631) 631
tyrosine kinase inhibitor (630) 630
oncology, experimental (618) 618
apoptosis (613) 613
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (581) 581
blast crisis (580) 580
survival (576) 576
hematopoietic stem cell transplantation (575) 575
protein-tyrosine kinases - antagonists & inhibitors (567) 567
cell biology (566) 566
bone marrow transplantation (562) 562
cells (557) 557
antineoplastic agents - pharmacology (550) 550
interferon-alpha (546) 546
article (542) 542
follow-up studies (535) 535
diagnosis (531) 531
stem-cell transplantation (530) 530
pyrimidines - pharmacology (527) 527
survival analysis (524) 524
myeloid leukemia (523) 523
tyrosine kinase (516) 516
follow-up (515) 515
pharmacology & pharmacy (514) 514
resistance (514) 514
recurrence (513) 513
gene expression (512) 512
pyrimidines - administration & dosage (508) 508
expression (507) 507
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (60) 60
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Online Resources - Online (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Credit Valley Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Toronto East General Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12128) 12128
Chinese (41) 41
German (33) 33
Japanese (32) 32
Russian (26) 26
Spanish (20) 20
French (13) 13
Korean (7) 7
Portuguese (5) 5
Czech (3) 3
Slovenian (3) 3
Hungarian (2) 2
Serbian (2) 2
Ukrainian (2) 2
Danish (1) 1
Polish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Haematologica, ISSN 0390-6078, 09/2016, Volume 101, Issue 10, pp. 1200 - 1207
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 25, pp. 6315 - 6321
Journal Article
American Journal of Hematology, ISSN 0361-8609, 12/2013, Volume 88, Issue 12, pp. 1024 - 1029
Most patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with tyrosine kinase inhibitors (TKI) achieve complete cytogenetic response... 
CHRONIC MYELOGENOUS LEUKEMIA | INTERFERON-ALPHA | THERAPY | CML | DASATINIB | HEMATOLOGY | ALPHA PLUS CYTARABINE | IMATINIB MESYLATE | DISCONTINUATION | NILOTINIB | REMISSION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Biomarkers, Tumor | RNA, Neoplasm - blood | Young Adult | Benzamides - therapeutic use | Fusion Proteins, bcr-abl - blood | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Neoplasm Proteins - genetics | Real-Time Polymerase Chain Reaction | Dasatinib | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Disease-Free Survival | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Survival Analysis | Neoplasm Proteins - blood | Aged | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Leukemia, Myeloid, Chronic-Phase - genetics | Tyrosine | Phenols | Care and treatment | Chronic myeloid leukemia | Analysis | Medical research | Leukemia | Index Medicus | tyrosine kinase inhibitors | chronic myeloid leukemia | molecular response | BCR-ABL
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 5/2012, Volume 68, Issue 5, pp. 723 - 733
We investigated the population pharmacokinetics and exposure-response relationship of nilotinib in patients with newly diagnosed chronic myeloid leukemia (CML)... 
Nilotinib | Population pharmacokinetics | Biomedicine | Chronic myeloid leukemia | Pharmacology/Toxicology | Exposure-response relationship | Pyrimidines - blood | Humans | Middle Aged | Biological Availability | Male | Metabolic Clearance Rate | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Leukemia, Myeloid, Chronic-Phase - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Aged | Cohort Studies | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Care and treatment | Myelocytic leukemia | Analysis | Electrocardiogram | Questions and answers | Electrocardiography | Nonlymphoid leukemia | Universities and colleges | Bilirubin | Antineoplastic agents | Drug therapy | Leukemia | Pharmacology | Index Medicus | EKG | Demography | Data processing | Dose-response effects | Models | Bioavailability | Regression analysis | Pharmacokinetics | Blood levels
Journal Article
Journal of Cancer Research and Clinical Oncology, ISSN 0171-5216, 6/2019, Volume 145, Issue 6, pp. 1645 - 1650
Journal Article
International Journal of Hematology, ISSN 0925-5710, 3/2017, Volume 105, Issue 3, pp. 233 - 234
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2013, Volume 88, Issue 5, pp. 350 - 354
Omacetaxine mepesuccinate (omacetaxine) is a first‐in‐class cephalotaxine with a unique mode of action, independent of BCR‐ABL, that has shown promising... 
CHRONIC MYELOGENOUS LEUKEMIA | CELLS | APOPTOSIS | THERAPY | BCR-ABL | IMATINIB | DOWN-REGULATION | HOMOHARRINGTONINE | HEMATOLOGY | FAILURE | NILOTINIB | Drug Resistance, Multiple | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Harringtonines - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Harringtonines - therapeutic use | Protein Synthesis Inhibitors - administration & dosage | Hematopoiesis - drug effects | Maintenance Chemotherapy - adverse effects | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Harringtonines - administration & dosage | Adult | Bone Marrow Cells - drug effects | Female | Antineoplastic Agents, Phytogenic - therapeutic use | Antineoplastic Agents, Phytogenic - adverse effects | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Bone Marrow Cells - pathology | Induction Chemotherapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Aged | Drug Monitoring | Protein Synthesis Inhibitors - adverse effects | Protein Synthesis Inhibitors - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Phenols | Research | Chronic myeloid leukemia | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 2016, Volume 101, Issue 3, pp. e86 - e90
Journal Article
Cancer Science, ISSN 1347-9032, 2010, Volume 101, Issue 10, pp. 2186 - 2192
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2014, Volume 74, Issue 1, pp. 85 - 93
We evaluated the population pharmacokinetics (PPK) and exposure–response relationship of imatinib mesylate in Iranian patients with chronic myeloid leukemia... 
Therapeutic drug monitoring | Population pharmacokinetics | Imatinib | Medicine & Public Health | Oncology | Cancer Research | Chronic myeloid leukemia | Pharmacology/Toxicology | TROUGH LEVEL | INDUSTRY | MOLECULAR RESPONSES | SAFETY | TYROSINE KINASE | ONCOLOGY | PLASMA-LEVELS | DRUG DEVELOPMENT | PHARMACOLOGY & PHARMACY | Piperazines - administration & dosage | Benzamides - pharmacokinetics | Pyrimidines - blood | Humans | Middle Aged | Male | Metabolic Clearance Rate | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Benzamides - administration & dosage | Benzamides - therapeutic use | Iran | Fusion Proteins, bcr-abl - blood | Adult | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Piperazines - blood | Leukemia, Myeloid, Chronic-Phase - metabolism | Protein Kinase Inhibitors - pharmacokinetics | Reproducibility of Results | Pyrimidines - administration & dosage | Benzamides - blood | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Piperazines - therapeutic use | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Bayes Theorem | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | ROC Curve | Aged | Drug Monitoring | Fusion Proteins, bcr-abl - metabolism | Drugstores | Chromatography | Index Medicus
Journal Article
International Journal of Hematology, ISSN 0925-5710, 2/2014, Volume 99, Issue 2, pp. 141 - 153
Journal Article
Blood, ISSN 0006-4971, 03/2003, Volume 101, Issue 5, pp. 1692 - 1697
We investigated the clinical activity of the farnesyl transferase inhibitor R115777 in 22 patients with chronic myelogenous leukemia (CML) in chronic,... 
IN-VITRO | THERAPY | ANGIOGENESIS | RAS SIGNALING PATHWAY | MECHANISMS | HEMATOLOGY | CANCER | ASTROCYTOMA-CELLS | ENDOTHELIAL GROWTH-FACTOR | FARNESYLTRANSFERASE INHIBITORS | PROTEIN PRENYLATION | Nausea - chemically induced | Vascular Endothelial Growth Factors | Humans | Lymphokines - blood | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Alkyl and Aryl Transferases - antagonists & inhibitors | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Primary Myelofibrosis - blood | Quinolones - therapeutic use | Multiple Myeloma - blood | Enzyme Inhibitors - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Enzyme Inhibitors - pharmacology | Fibroblast Growth Factor 2 - blood | Enzyme Inhibitors - therapeutic use | Farnesyltranstransferase | Tumor Necrosis Factor-alpha - analysis | Endothelial Growth Factors - blood | Quinolones - administration & dosage | Blast Crisis - blood | Vascular Endothelial Growth Factor A | Blast Crisis - drug therapy | Salvage Therapy | Quinolones - pharmacology | Intercellular Signaling Peptides and Proteins - blood | Multiple Myeloma - drug therapy | Quinolones - adverse effects | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacology | Leukemia, Myeloid, Accelerated Phase - blood | Drug Eruptions - etiology | Primary Myelofibrosis - drug therapy | Leukemia, Myeloid, Accelerated Phase - drug therapy | Drug Administration Schedule | Leukemia, Myeloid, Chronic-Phase - blood | Treatment Outcome | Hepatocyte Growth Factor - blood | Interferon-alpha - blood | Neoplasm Proteins - blood | Aged | Index Medicus | Abridged Index Medicus
Journal Article